Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial

Boehringer Ingelheim

Boehringer Ingelheim trial registry — 202 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE HQ
46,699 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
Employees
46,699
Programs
193
Drugs
113
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Trials

Boehringer Ingelheim clinical trials

Registry index of 202 ClinicalTrials.gov studies linked to Boehringer Ingelheim programs — each row shows trial ID, program name, phase, status, and indication.

Boehringer Ingelheim trial registry — 202 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Boehringer Ingelheim.

  1. 1519-0001 — Phase 1

    Clinical update

  2. 1509-0007 — Phase 1

    Clinical update

  3. 1493-0008 — Phase 1

    Clinical update

  4. 1404-0009 — Phase 1

    Clinical update

  5. 1305-0039 — Phase 1

    Clinical update

  6. 1305-0037 — Phase 1

    Clinical update

  7. 2007-0001 — Phase 1

    Clinical update

  8. 2001-0001 — Phase 1

    Clinical update

Trial registry

202 studies
  11. 2023-505870-13-00

    1438-0007

    Phase 1 active other

    Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)

    CTIS ↗
  31. 2023-509566-38-00

    1479-0012

    Phase 2 active small_molecule

    gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma

    CTIS ↗
  76. 2024-514621-29-00

    0352-2189

    Phase 1 active other

    1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B

    CTIS ↗
  77. 2024-514622-22-00

    0352-2190

    Phase 1 active other

    1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B

    CTIS ↗
  119. 2025-522913-45-00

    2001-0001

    Phase 1 active other

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.